OBJECTIVE: To report a novel prion disease characterized by distinct histopathological and immunostaining features, and associated with an abnormal isoform of the prion protein (PrP) that, contrary to the common prion diseases, is predominantly sensitive to protease digestion. METHODS: Eleven subjects were investigated at the National Prion Disease Pathology Surveillance Center for clinical, histopathological, immunohistochemical, genotypical, and PrP characteristics. RESULTS: Patients presented with behavioral and psychiatric manifestations on average at 62 years, whereas mean disease duration was 20 months. The type of spongiform degeneration, the PrP immunostaining pattern, and the presence of microplaques distinguished these cases from those with known prion diseases. Typical protease-resistant PrP was undetectable in the cerebral neocortex with standard diagnostic procedures. After enrichment, abnormal PrP was detected at concentrations 16 times lower than common prion diseases; it included nearly 4 times less protease-resistant PrP, which formed a distinct electrophoretic profile. The subjects examined comprised about 3% of sporadic cases evaluated by the National Prion Disease Pathology Surveillance Center. Although several subjects had family histories of dementia, no mutations were found in the PrP gene open reading frame. INTERPRETATION: The distinct histopathological, PrP immunohistochemical, and physicochemical features, together with the homogeneous genotype, indicate that this is a previously unidentified type of disease involving the PrP, which we designated "protease-sensitive prionopathy" (or PSPr). Protease-sensitive prionopathy is not rare among prion diseases, and it may be even more prevalent than our data indicate because protease-sensitive prionopathy cases are likely also to be classified within the group of non-Alzheimer's dementias.
OBJECTIVE: To report a novel prion disease characterized by distinct histopathological and immunostaining features, and associated with an abnormal isoform of the prion protein (PrP) that, contrary to the common prion diseases, is predominantly sensitive to protease digestion. METHODS: Eleven subjects were investigated at the National Prion Disease Pathology Surveillance Center for clinical, histopathological, immunohistochemical, genotypical, and PrP characteristics. RESULTS:Patients presented with behavioral and psychiatric manifestations on average at 62 years, whereas mean disease duration was 20 months. The type of spongiform degeneration, the PrP immunostaining pattern, and the presence of microplaques distinguished these cases from those with known prion diseases. Typical protease-resistant PrP was undetectable in the cerebral neocortex with standard diagnostic procedures. After enrichment, abnormal PrP was detected at concentrations 16 times lower than common prion diseases; it included nearly 4 times less protease-resistant PrP, which formed a distinct electrophoretic profile. The subjects examined comprised about 3% of sporadic cases evaluated by the National Prion Disease Pathology Surveillance Center. Although several subjects had family histories of dementia, no mutations were found in the PrP gene open reading frame. INTERPRETATION: The distinct histopathological, PrP immunohistochemical, and physicochemical features, together with the homogeneous genotype, indicate that this is a previously unidentified type of disease involving the PrP, which we designated "protease-sensitive prionopathy" (or PSPr). Protease-sensitive prionopathy is not rare among prion diseases, and it may be even more prevalent than our data indicate because protease-sensitive prionopathy cases are likely also to be classified within the group of non-Alzheimer's dementias.
Authors: Wen-Quan Zou; Jian Zheng; Donald M Gray; Pierluigi Gambetti; Shu G Chen Journal: Proc Natl Acad Sci U S A Date: 2004-01-20 Impact factor: 11.205
Authors: P Parchi; R Castellani; S Capellari; B Ghetti; K Young; S G Chen; M Farlow; D W Dickson; A A Sima; J Q Trojanowski; R B Petersen; P Gambetti Journal: Ann Neurol Date: 1996-06 Impact factor: 10.422
Authors: R J Kascsak; R Rubenstein; P A Merz; M Tonna-DeMasi; R Fersko; R I Carp; H M Wisniewski; H Diringer Journal: J Virol Date: 1987-12 Impact factor: 5.103
Authors: Qingzhong Kong; Shenghai Huang; Wenquan Zou; Difernando Vanegas; Meiling Wang; Di Wu; Jue Yuan; Mengjie Zheng; Hua Bai; Huayun Deng; Ken Chen; Allen L Jenny; Katherine O'Rourke; Ermias D Belay; Lawrence B Schonberger; Robert B Petersen; Man-Sun Sy; Shu G Chen; Pierluigi Gambetti Journal: J Neurosci Date: 2005-08-31 Impact factor: 6.167
Authors: David W Colby; Qiang Zhang; Shuyi Wang; Darlene Groth; Giuseppe Legname; Detlev Riesner; Stanley B Prusiner Journal: Proc Natl Acad Sci U S A Date: 2007-12-20 Impact factor: 11.205
Authors: Patrick Tremblay; Haydn L Ball; Kiyotoshi Kaneko; Darlene Groth; Ramanujan S Hegde; Fred E Cohen; Stephen J DeArmond; Stanley B Prusiner; Jiri G Safar Journal: J Virol Date: 2004-02 Impact factor: 5.103
Authors: Shawn Browning; Christopher A Baker; Emery Smith; Sukhvir P Mahal; Maria E Herva; Cheryl A Demczyk; Jiali Li; Charles Weissmann Journal: J Biol Chem Date: 2011-09-19 Impact factor: 5.157
Authors: Christina J Sigurdson; Shivanjali Joshi-Barr; Cyrus Bett; Olivia Winson; Giuseppe Manco; Petra Schwarz; Thomas Rülicke; K Peter R Nilsson; Ilan Margalith; Alex Raeber; David Peretz; Simone Hornemann; Kurt Wüthrich; Adriano Aguzzi Journal: J Neurosci Date: 2011-09-28 Impact factor: 6.167
Authors: Daryl Rhys Jones; Marion Delenclos; AnnMarie T Baine; Michael DeTure; Melissa E Murray; Dennis W Dickson; Pamela J McLean Journal: J Neuropathol Exp Neurol Date: 2015-12 Impact factor: 3.685